4D Molecular Therapeutics, Inc. 8K

4D Molecular Therapeutics reported Q2 2026 results, detailed progress and timelines for its late-stage ophthalmology and cystic fibrosis programs, and strengthened liquidity via a new up-to-$200 million credit facility with Hercules Capital, supporting operations into the second half of 2028.

On August 13, 2026, 4D Molecular Therapeutics, Inc. reported its second quarter 2026 financial results and operational updates, highlighting completion of enrollment in its two global Phase 3 4FRONT trials of lead candidate 4D-150 for wet age-related macular degeneration with topline data expected in 2027, plans to initiate a Phase 3 trial of 4D-150 in diabetic macular edema in the third quarter of 2026, and additional milestones including upcoming data readouts for other pipeline programs. The company also disclosed that it entered into a strategic credit facility agreement with Hercules Capital, Inc. for up to $200 million, from which it drew an initial $20 million at closing, to enhance financial and operational flexibility. As of June 30, 2026, 4DMT held approximately $430.6 million in cash, cash equivalents and marketable securities, reported collaboration revenue primarily from its Otsuka agreement, higher R&D expenses driven by Phase 3 trial execution, and a net loss of $72.9 million for the quarter, and stated that its current capital resources are expected to fund operations into the second half of 2028. The company additionally announced it will host an Investor Day in New York City on October 21, 2026 to discuss the commercial potential of 4D-150 and broader pipeline progress.

Filing Facts

CIK

1650648

Ticker

FDMT

Form

8K

Source Type

fda

Accession

0001193125-26-349160

Alert Tier

6